← Eichor
Study identifier: NCT06810505 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Condition: Chronic Migraine  ·  Sponsor: AbbVie

PhasePhase 3
Planned participants420
Who can joinAll sexes, 12 Years to 17 Years
Healthy volunteersNo

About this study

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world. Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks. Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing qu…

This description comes directly from the study's public registry record.

Talk to the study team

ABBVIE CALL CENTER  ·  844-663-3742  ·  abbvieclinicaltrials@abbvie.com

Always discuss trial participation with your own doctor first.

Locations (64)

Rehabilitation and Neurological Services /ID# 270782Huntsville, Alabama, United StatesRecruiting
Preferred Research Partners - Fayetteville /ID# 270419Fayetteville, Arkansas, United StatesCompleted
Preferred Research Partners /ID# 270389Little Rock, Arkansas, United StatesRecruiting
Advanced Research Center /ID# 270257Anaheim, California, United StatesRecruiting
Neuro Pain Research Center /ID# 271048Fresno, California, United StatesRecruiting
Accellacare - Long Beach /ID# 270398Long Beach, California, United StatesRecruiting
Excell Research /ID# 270258Oceanside, California, United StatesRecruiting
Lumos Clinical Research Center /ID# 270582San Jose, California, United StatesRecruiting
Sunwise Clinical Research /ID# 270431Walnut Creek, California, United StatesRecruiting
Northwest Florida Clinical Research Group, LLC /ID# 270833Gulf Breeze, Florida, United StatesRecruiting
Auzmer Research /ID# 271158Lakeland, Florida, United StatesCompleted
My Preferred Research /ID# 270312Miami, Florida, United StatesRecruiting

+ 52 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06810505